Movement disorders encompass a variety of neurological conditions that affect a person’s ability to control voluntary and involuntary movements. Patients may experience symptoms such as tremors, stiffness, slow movements, or abnormal postures, which can significantly impact daily life. In diagnosing and managing these complex disorders, movement disorder specialists play a crucial role. These neurologists have advanced training focused on conditions like Parkinson’s disease, dystonia, essential tremor, and Huntington’s disease. They use detailed clinical assessments, imaging studies, and sometimes genetic testing to identify the specific disorder and tailor treatment plans accordingly.
The approach of movement disorder specialists often involves a combination of medication management, physical therapy, and in some cases, surgical interventions like deep brain stimulation. They work closely with multidisciplinary teams including physical therapists, occupational therapists, and speech therapists to provide comprehensive care. Their expertise not only improves symptom control but also helps patients maintain independence and quality of life. Additionally, movement disorder specialists contribute to research and clinical trials, pushing forward new treatments and improving understanding of these conditions. Their specialized knowledge is vital in addressing the challenges faced by patients with movement disorders, offering hope and support through advanced neurological care. As research progresses, these specialists continue to expand treatment options, striving to improve outcomes for all patients.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States